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Dear Editor,
L
eonardi  and  La  Rosa  (1)  investigated  the 
occurrence of celiac disease in patients with 
hepatitis B by screening their sera with anti-endomysial 
and anti-tissue transglutaminase antibodies—both of 
which are sensitive serological tests for celiac disease. 
The authors found no one with celiac disease in 60 
patients who had contracted hepatitis B infection in 
childhood. As they admitted, the power of the study 
was too low to make any definitive conclusions.
Celiac  disease  is  defined  as  “a  permanent 
intolerance to ingested gluten, the structural protein 
in wheat rye and barley.” The ingestion of gluten 
results in small bowel mucosal inflammation, crypt 
hyperplasia and villous atrophy. Typically, patients 
suffer from diarrhea, abdominal complaints, malaise, 
and  malabsorption  with  resultant  iron  deficiency 
anemia. The histpathology and symptoms resolve on 
gluten-free diet.
Of note, the condition is often asymptomatic. 
Extraintestinal  manifestations  or  associated 
autoimmune conditions may be the sole presentations 
of celiac disease. Here, I disagree with Leonardi and 
La Rosa (1) who stated that associated autoimmune 
diseases  are  usually  found  in  celiac  patients  with 
severe complications: existing autoimmune disorders 
(e.g., autoimmune hepatitis) may be the only disease 
manifestation in an otherwise asymptomatic celiac 
patient (2).
Isolated  hypertransaminasemia  is  common 
in  celiac  disease,  and  conversely,  unexplained 
hypertransaminasemia  may  be  a  diagnostic  clue 
in celiac disease. Celiac disease has been reported 
to occur in patients with primary biliary cirrhosis, 
autoimmune  hepatitis  and  primary  sclerosing 
cholangitis (3). Untreated celiac disease may exacerbate 
the associated liver disease, and gluten-free dietary 
treatment in such cases, may result in a dramatic 
improvement, even in advanced liver disease (4) .
As to the viral hepatitis, there are more studies on 
the occurrence of celiac disease in hepatitis C than in 
hepatitis B. Two large studies comprising 624 (5) and 
878 (6) patients with hepatitis C found no increased 
frequency of celiac disease. The positive associations 
are mainly based on case reports.
When considering the reports, some facts must 
be taken into account. Firstly, celiac disease affects 
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more than 1% of people in many countries, which 
means that the disease associations may be fortuitous. 
For instance, if we make an estimate that 1% of the 
population in Italy is infected by hepatitis B virus, it 
means that 6000 people with hepatitis B will have 
(mostly undetected) celiac disease; and there would 
be even more cases with hepatitis C and celiac disease. 
Secondly, symptoms of celiac disease are variable and 
subtle. There are case reports where celiac disease has 
been activated after the commencement of interferon 
therapy  (6).  This  is  yet  to  be  proved,  however. 
Patients treated with interferon are usually kept on 
careful  surveillance,  and  side-effects  of  interferon 
may mimic symptoms of celiac disease (i.e., anemia, 
depression,  and  fatigue).  It  is  thus  possible  that 
serologic screening will be carried out more easily in 
patients who have received medical therapy for viral 
hepatitis than in other patients suffering from similar 
symptoms. Nevertheless, the development of celiac 
disease should be kept in mind during interferon 
therapy, as the drug may activate latent autoimmune 
diseases.
Evidence suggests that patients with celiac disease 
have a lower response rate to hepatitis B vaccination 
than healthy subjects. This failure to respond may 
increase the risk of hepatitis B in celiac disease (7).
To conclude, at the moment, there is no convincing 
evidence that patients with viral hepatitis carry an 
increased risk of celiac disease. The results of Leonardi 
and La Rosa (1) support this conclusion. However, 
the  protean  and  subtle  clinical  manifestations  of 
celiac disease should be remembered when treating 
patients with hepatitis B or C.
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